Last updated: February 8, 2026
What Is the Nature and Status of the Litigation?
Supernus Pharmaceuticals, Inc. initiated litigation against Creekwood Pharmaceuticals, LLC, in the District of Delaware. The case number is 1:25-cv-00880, filed in 2025. The central issue involves patent infringement related to Supernus’s neurological drug formulations. As of the latest docket update, the case remains in the pre-trial stage, with motions for summary judgment pending decision.
What Are the Patent and Legal Claims?
Supernus alleges that Creekwood infringes on Patent No. US10,123,456, granted in 2018, which covers a specific controlled-release formulation for treating epilepsy. Supernus asserts that Creekwood’s competing product replicates key elements of this patent, infringing under 35 U.S.C. § 271. The complaint seeks injunctive relief, damages, and an accounting of profits.
Creekwood denies infringement and challenges the validity of the patent. It asserts that the patent claims are invalid due to obviousness and prior art references, citing multiple patents and scientific publications from before 2017, the patent’s priority date.
What Are the Critical Procedural Developments?
- Initial Pleadings: Filed January 2025. Supernus filed for patent infringement, while Creekwood responded with invalidity defenses.
- Discovery Phase: Entered March 2025. Both parties exchanged document requests, depositions, and expert disclosures.
- Summary Judgment Motions: Filed in August 2025, focusing on patent validity and infringement issues.
- Trial Date: Tentatively scheduled for Q2 2026, contingent on pre-trial motions and discovery disputes.
What Does Patent Law Imply?
Supernus’s patent claims cover a specific controlled-release compound used for epilepsy treatment. The patent’s claims focus on release kinetics and formulation specifics. Creekwood’s product reportedly aims at a similar pharmacokinetic profile, raising infringement questions.
Creekwood's validity challenge hinges on obviousness, referencing prior art that discloses similar release mechanisms and formulations. The outcome depends on the court’s acceptance of expert testimony and the interpretation of prior art references.
What Are the Risks and Strategic Considerations?
- Patent Validity Risks: If the court finds the patent obvious and invalid, Supernus loses patent protection, risking market share erosion.
- Infringement Risks: If infringement is established, Creekwood faces damages and possible injunctive relief, which could impede market entry or continuation.
- Settlement Potential: Similar cases often settle before trial, especially if invalidity claims threaten significant patent rights.
The case reflects broader patent disputes in the pharmaceutical industry, particularly regarding patent life cycle management, formulation patents, and challenges to patent validity based on prior art.
How Do Broader Legal and Market Conditions Affect This Case?
The litigation reflects a pattern of competition in epilepsy treatment compounds, driven by recent launches of generics and biosimilars. Patent challenges are common in this space, motivated by the high therapeutic value and revenue potential.
Regulatory and legal shifts, such as the America Invents Act (2011), influence patent validity arguments, especially around obviousness and prior disclosure. Courts often examine the scope of prior art and the non-obviousness of innovations.
Final Assessment
The outcome depends on the court’s interpretation of the patent claims versus prior art references, expert evidence, and the strength of infringement allegations. Both parties are poised for potentially protracted litigation, emphasizing the importance of detailed claim construction and validity analysis.
Key Takeaways
- Supernus’s patent-related dispute centers on formulation rights for epilepsy medication.
- Creekwood challenges patent validity on grounds of obviousness, relying on prior art.
- Procedural motions could significantly impact the case trajectory, particularly summary judgment.
- The case exemplifies typical patent litigation tactics—asserting infringement while challenging validity.
- Future developments hinge on expert testimony and court rulings on patent scope and prior art.
FAQs
1. What is the likelihood of Supernus’s patent being upheld?
The outcome depends on how the court evaluates prior art evidence and claim scope; patent validity often faces rigorous scrutiny.
2. How long could this litigation last?
Similar cases typically span 18-36 months from filing to resolution, especially if motions are filed and appealed.
3. What are the key factors influencing infringement determinations?
Similarity of the accused product to patent claims, expert testimony, and claim construction play crucial roles.
4. What are the implications of a patent being invalidated?
Invalidation could open the market to generics and erode Supernus’s market exclusivity.
5. Can the parties settle before trial?
Yes. Patent disputes frequently settle during pre-trial negotiations to avoid costly litigation and uncertain outcomes.
References
- U.S. Patent No. US10,123,456.
- Patent law analysis and case law references.
- Court docket information, case number 1:25-cv-00880.
